"Alfa-Pharm" is issuing bonds for the first time, totaling 1.5 billion drams, with Ameriabank serving as underwriter
YEREVAN, December 9. /АРКА/. Today, "Alfa-Pharm" CJSC announced the launch of sales for 15,000 nominal coupon dram bonds. According to the bank's press service, Ameriabank is the underwriter for these bonds.
The funds generated from this bond placement will be allocated for capital expenditures. Each bond has a nominal value of 100,000 drams, with an annual coupon rate of 11.3% (payments are made annually), and the minimum purchase requirement is 5 bonds. The bonds will have a circulation period of 36 months.
Sales of the bonds will commence on December 10, 2025, and conclude on February 11, 2026, or sooner if the entire volume is sold out before the end date.
Regarding the bond issuance, the company emphasizes that one of "Alfa-Pharm"'s main priorities is to invest continuously in healthcare initiatives, providing innovative solutions to the public and ensuring high-quality services.
Pharmacy chains play a crucial role in the healthcare system, supplying the population with essential medications and accessories, while also holding social and strategic significance for the sustainable development of the industry.
"The public offering of Alfa-Pharm bonds signifies the start of a new phase in our company's growth, grounded in profitability, stable cash flows, an effective business model, technological advancements, and a leading market position. Our competitive strengths enable us to confidently enter the Armenian capital market and invite investors to engage in financing our strategic programs under favorable conditions. We believe that the bond placement will foster the company's growth and help fulfill our mission to advance the healthcare sector in Armenia," stated Alfa-Pharm CEO Mikael Matsakyan.
Bonds can be acquired online via the MyInvest application from Ameriabank MyAmeria, or by visiting any Ameriabank branch to complete the application form. Alternatively, you can send the filled application form to Ameriabank's email address: capitalmarkets@ameriabank.am.
Following the initial placement, the company will seek to list the bonds on the Armenian Stock Exchange, allowing for their purchase or sale in the secondary market.
The bond issue prospectus for "Alfa-Pharm" was registered by the chairman of the Central Bank of Armenia on November 26, 2025. You can find the bond purchasing procedure, the electronic version of the issue prospectus, and announcements regarding the public placement of bonds here.
The prospectus contains all the details about the issue and the proposed bonds, along with the associated risks.
About "Alfa-Pharm"
The "Alfa-Pharm" pharmacy chain is the largest in Armenia, boasting around 210 pharmacies across the republic. Over its 30 years of operation, the company has consistently prioritized high-quality service, as reflected in the satisfaction and positive feedback from numerous clients. "Alfa-Pharm" serves as the official and exclusive representative for several renowned global brands in the market.
The company exclusively imports well-known care products such as Avene, Ducray, A-Derma, La Roche Posay, Vichy, Cerave, Bioderma, Frezyderm, and Mustela, along with baby care and feeding products like Bambo Nature, Danalac, Wet Brush, and Beter. Additionally, "Alfa-Pharm" is actively expanding its range of vitamins and dietary supplements, importing popular global brands like Natures Plus, New Nordic, Jarrow Formulas, Nature's Bounty, and others.
The pharmacy chain "Alfa-Pharm" is also known as the first online pharmacy in Armenia, offering 24/7 delivery and consultation services since its establishment in 2018. This state-of-the-art, multifunctional online pharmacy can be accessed via the mobile app and the website www.alfapharm.am, enabling customers to order essential medications, cosmetics, and children's items at any time. ($1 - 381.66 drams).-0-
